Literature DB >> 7962338

Interleukin-6: a marker of thyroid-destructive processes?

L Bartalena1, S Brogioni, L Grasso, T Rago, P Vitti, A Pinchera, E Martino.   

Abstract

Increased serum interleukin-6 (IL-6) concentrations have recently been reported in patients with subacute thyroiditis and in some patients with amiodarone-induced thyrotoxicosis, possibly because of cytokine release from damaged thyroid cells. In this study, serum IL-6 levels were determined by an enzyme-linked immunosorbent assay method in 18 patients given percutaneous intranodular ethanol injection (PIEI) for autonomously functioning thyroid nodule, 12 patients treated with radioactive iodine (RAI) for Graves' disease or toxic adenoma, and 23 patients submitted to fine needle aspiration (FNA) for nonfunctioning thyroid nodules. Baseline serum IL-6 levels did not differ in the 3 groups. PIEI was followed by a dramatic increase in median IL-6 values from 42 fmol/L (range, < 25 to 84) to 381 fmol/L (range, 61-9870; P < 0.0001); the peak value was attained as little as 10 min after injection. RAI was also followed by a significant (P < 0.0001) increase in IL-6 from 52 fmol/L (range, < 25 to 84) to 189 fmol/L (range, 119-1417 fmol/L); the increase after RAI was lower than that after PIEI (P < 0.05), and the peak value was attained later (after 24 h). FNA was also followed by a slight, but significant, increase in the serum IL-6 concentration from 21 fmol/L (range, < 25 to 103) to 109 fmol/L (range, < 25 to 360; P < 0.0001 vs. baseline). The increase in IL-6 was correlated with the size of nodule or goiter (P < 0.0001), but not with the amount of injected ethanol or the dose of radioiodine delivered to the thyroid. Serum thyroglobulin also increased after PIEI, RAI, or FNA, but no significant correlation could be demonstrated with the increase in IL-6. The results of this study support the concept that in the absence of nonthyroidal illnesses, which are often associated with increased serum concentrations of the cytokine, IL-6 can be regarded as a useful marker of thyroid-destructive processes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962338     DOI: 10.1210/jcem.79.5.7962338

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Appearance of Graves' disease after percutaneous ethanol injection for the treatment of hyperfunctioning thyroid adenoma.

Authors:  F Monzani; P Del Guerra; N Caraccio; A Casolaro; P V Lippolis; O Goletti
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

2.  Immunohistochemical localization of interleukin-6 in peripheral human endocrine glands.

Authors:  George Kontogeorgos; Irene Messini; Efi Kyrodimou; Linda Giannikaki; Emmanuel Zois; George Koukoulis; Stylianos Tsagarakis
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.633

Review 3.  Effects of amiodarone therapy on thyroid function.

Authors:  Janna Cohen-Lehman; Peter Dahl; Sara Danzi; Irwin Klein
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

Review 4.  Pain and thyroid hormones.

Authors:  Anna Maria Aloisi; Stella Vodo; Michelangelo Buonocore
Journal:  Neurol Sci       Date:  2013-04-23       Impact factor: 3.307

5.  Coexistence of subacute thyroiditis and renal cell carcinoma: a paraneoplastic syndrome.

Authors:  Ekrem Algün; Süleyman Alici; Cevat Topal; Serdar Ugras; Reha Erkoç; M Emin Sakarya; Nese Ozbey
Journal:  CMAJ       Date:  2003-04-15       Impact factor: 8.262

6.  Amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge.

Authors:  Umang Barvalia; Barkha Amlani; Ram Pathak
Journal:  Case Rep Med       Date:  2014-11-12

Review 7.  Cytokines in Endocrine Dysfunction of Plasma Cell Disorders.

Authors:  Eva Feigerlová; Shyue-Fang Battaglia-Hsu
Journal:  Mediators Inflamm       Date:  2017-06-27       Impact factor: 4.711

Review 8.  Prognostic implications of thyroid hormone alterations in acute coronary syndrome-A systematic review.

Authors:  Priyadarshini Arambam; Upendra Kaul; Priya Ranjan; Rajiv Janardhanan
Journal:  Indian Heart J       Date:  2020-11-23

9.  Dysfunction of the thyroid gland during amiodarone therapy: a study of 297 cases.

Authors:  Agata Czarnywojtek; Maria Teresa Płazińska; Małgorzata Zgorzalewicz-Stachowiak; Kosma Woliński; Adam Stangierski; Izabela Miechowicz; Joanna Waligórska-Stachura; Paweł Gut; Leszek Królicki; Maja Zioncheck; Marek Ruchała
Journal:  Ther Clin Risk Manag       Date:  2016-04-04       Impact factor: 2.423

10.  Significance of Interleukin-6 in Papillary Thyroid Carcinoma.

Authors:  Toral P Kobawala; Trupti I Trivedi; Kinjal K Gajjar; Darshita H Patel; Girish H Patel; Nandita R Ghosh
Journal:  J Thyroid Res       Date:  2016-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.